Download Mobile App

Video Library

Events

more events

12 Dec 2025 - 14 Dec 2025

44th Medicall Expo

20 Jan 2026 - 21 Jan 2026

MedHealth 2026 - The 26th Forum of the Arab Hospitals Federation

29 Jan 2026 - 31 Jan 2026

Medical Fair India 2026 - Delhi 31st Edition

Partner Sites

MedImaging

3D Scanning Approach Enables Ultra-Precise Brain Surgery

X-Ray Breakthrough Captures Three Image-Contrast Types in Single Shot

Novel Imaging Approach to Improve Treatment for Spinal Cord Injuries

Radiotheranostic Approach Detects, Kills and Reprograms Aggressive Cancers

AI Tool Improves Medical Imaging Process by 90%

Cardinal to Acquire Cordis Vascular Technology for USD 1.94 Billion

By HospiMedica International staff writers
Posted on 15 Mar 2015

US pharmaceutical and medical equipment maker Johnson & Johnson (J&J; New Brunswick, NJ, USA) has agreed to sell its Cordis vascular technology unit to Cardinal Health (Dublin, OH, USA) for USD 1.94 billion.

The acquisition follows a sequence of strategic moves for Cardinal Health in the areas of cardiology, wound management, and orthopedics, and is designed to elevate Cardinal Health to the status of a global manufacturer of cardiology and endovascular devices, as well as providing an opportunity to build a generic medical devices business that could be a powerful competitor to cardiovascular device companies such as Abbott Laboratories, Boston Scientific (Natick, MA, USA), and Medtronic.

The purchase of Cordis (Fremont, CA, USA) marks the continued departure of J&J from the cardiovascular stent business, a move that enables the company to focus on other areas that offer greater opportunities for growth. More...

J&J said, however, that it would continue to stay in the cardiovascular disease sector through its electrophysiology business, Biosense Webster, and its leading cardiovascular treatment Xarelto.

“With an aging population and the accompanying demand for less invasive medical treatments, health systems around the world are searching for the best way to bring quality care to their patients in the most cost-effective way,” said George Barrett, chairman and CEO of Cardinal Health. “The acquisition of Cordis reinforces our strategic position to address this need and strengthens an important growth driver in the Cardinal Health portfolio.”

“This initiative is part of our ongoing disciplined portfolio management approach to focus on our most promising opportunities to help patients and drive growth,” said Gary Pruden, worldwide chairman of the global surgery group at J&J. “Cordis has made significant contributions to the field of cardiovascular care, and we believe the business has a promising future with Cardinal Health, a company with which we have a long-standing relationship.”

Related Links:
Johnson & Johnson
Cardinal Health
Cordis

Visit expo >

Gold Member

12-Channel ECG

CM1200B

Antipsychotic TDM Assays
Saladax Antipsychotic Assays

Radiation Safety Barrier

RayShield Intensi-Barrier

Bipolar Coagulation Generator

Aesculap

Read the full article by registering today, it's FREE!

Free digital version edition of HospiMedica International sent by email on regular basis
Free print version of HospiMedica International magazine (available only outside USA and Canada).
Free and unlimited access to back issues of HospiMedica International in digital format
Free HospiMedica International Newsletter sent every week containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!